| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA4869735
Max Phase: Preclinical
Molecular Formula: C23H19F6N5O2
Molecular Weight: 511.43
Molecule Type: Unknown
Associated Items:
Representations
Canonical SMILES: Cc1ccc(C2=C(c3nnn[nH]3)C(=O)N[C@@](c3ccc(OCCC(F)(F)F)cc3)(C(F)(F)F)C2)cc1
Standard InChI: InChI=1S/C23H19F6N5O2/c1-13-2-4-14(5-3-13)17-12-21(23(27,28)29,30-20(35)18(17)19-31-33-34-32-19)15-6-8-16(9-7-15)36-11-10-22(24,25)26/h2-9H,10-12H2,1H3,(H,30,35)(H,31,32,33,34)/t21-/m0/s1
Standard InChI Key: WTNRKFSHXGHJFJ-NRFANRHFSA-N
Associated Targets(Human)
Alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase 703 Activities
Associated Targets(non-human)
Alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase 71 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 511.43 | Molecular Weight (Monoisotopic): 511.1443 | AlogP: 4.73 | #Rotatable Bonds: 6 |
| Polar Surface Area: 92.79 | Molecular Species: ACID | HBA: 5 | HBD: 2 |
| #RO5 Violations: 1 | HBA (Lipinski): 7 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 1 |
| CX Acidic pKa: 3.41 | CX Basic pKa: | CX LogP: 4.91 | CX LogD: 3.36 |
| Aromatic Rings: 3 | Heavy Atoms: 36 | QED Weighted: 0.47 | Np Likeness Score: -0.69 |
References
| 1. Turdi H, Chao H, Hangeland JJ, Ahmad S, Meng W, Brigance R, Zhao G, Wang W, Moore F, Ye XY, Mathur A, Hou X, Kempson J, Wu DR, Li YX, Azzara AV, Ma Z, Chu CH, Chen L, Cullen MJ, Rooney S, Harvey S, Kopcho L, Panemangelor R, Abell L, O'Malley K, Keim WJ, Dierks E, Chang S, Foster K, Apedo A, Harden D, Dabros M, Gao Q, Pelleymounter MA, Whaley JM, Robl JA, Cheng D, Lawrence RM, Devasthale P.. (2021) Screening Hit to Clinical Candidate: Discovery of BMS-963272, a Potent, Selective MGAT2 Inhibitor for the Treatment of Metabolic Disorders., 64 (19.0): [PMID:34613725] [10.1021/acs.jmedchem.1c01356] |
Source
Source(1):